Drug intelligence / Profile preview

PSM915

Development stage: Preclinical
Lead developer: PrecisemAb Biotech
Modality: Antibody-Based Therapeutics

Overview

**PSM915** is a tumor-selective activating antibody developed by PrecisemAb Biotech Co., Ltd. It is part of the company's pipeline of antibody programs designed for tumor-selective activation, leveraging mechanisms that enable precise targeting within the tumor microenvironment to enhance therapeutic efficacy while minimizing off-target effects. Currently in the discovery stage, it is being advanced for potential applications in oncology, particularly within immune-mediated therapeutic areas, though specific indications, mechanisms, and preclinical data remain limited in public disclosures.

Targets

TNFA (Tumor necrosis factor alpha (soluble))IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on PSM915.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSM915.

Explore the full profile